Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology

Sector: Healthcare

Phone: 403 670 7377

Fax: 403 283 0858

Website: oncolyticsbiotech.com

Address:

322 11th Avenue SW, Suite 804, Calgary, Canada

saxy4u Apr. 18 at 6:39 PM

$ONCY AIO GOBLET RECRUITMENT COMPLETED UPDATED 116/137 INCLUDED UPDATED APRIL 17 2026 https://www.aio-portal.de/studie/108--goblet.html

0 · Reply

saxy4u Apr. 18 at 5:04 PM

$ONCY https://www.linkedin.com/posts/avishekbasu24_patent-biologics-biosimilars-share-7451149261200842754-GihP?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAZPeTUB2cyiOZxf0FYiQiXQJIZPwU5o3JY&utm_campaign=copy_link

0 · Reply

EscapePlan Apr. 18 at 12:46 PM

$ONCY At the AACR Annual Meeting 2026, Oncolytics Biotech (ONCY) is presenting two posters that are scheduled for Sunday, April 19, 2026. The specific presentation details for pelareorep are as follows: Pancreatic Cancer (GOBLET Trial): Title: Pelareorep combined with atezolizumab and chemotherapy shows immune conversion activity in advanced pancreatic cancer: Biomarker results of cohort 1 of the GOBLET trial. Time: 2:00 p.m. – 5:00 p.m. PT. Location: Poster Section. Breast Cancer (AWARE-1 Study): Title: Imaging and biomarker data from the AWARE-1 study of pelareorep in early breast cancer. Time: 2:00 p.m. – 5:00 p.m. PT. Location: Poster

5 · Reply

saxy4u Apr. 18 at 2:35 AM

$ONCY AstraZeneca, Pfizer and Roche!

3 · Reply

saxy4u Apr. 17 at 8:58 PM

$ONCY see everyone Monday! Let’s all hope we get what we want! Cheers

0 · Reply

GoPatzGo123 Apr. 17 at 7:34 PM

$ONCY fuck all here so far.

1 · Reply

uptrend2025 Apr. 17 at 5:45 PM

$ONCY 👀

0 · Reply

m00nsh0t Apr. 17 at 4:34 PM

$ONCY getting some action to the upside

0 · Reply

saxy4u Apr. 17 at 2:49 PM

$ONCY $1.25 EOD?

2 · Reply

GoPatzGo123 Apr. 17 at 11:18 AM

$ONCY this thanks @saxy4u 👇👇👇👇👇👇👇👇👇

1 · Reply

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Apr 1, 2026, 9:00 AM EDT - 17 days ago

Oncolytics Biotech® Completes Domicile Change to the United States

Mar 19, 2026, 9:00 AM EDT - 4 weeks ago

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Mar 2, 2026, 9:00 AM EST - 6 weeks ago

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Feb 24, 2026, 9:00 AM EST - 7 weeks ago

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Feb 4, 2026, 8:50 AM EST - 2 months ago

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Jan 15, 2026, 4:01 PM EST - 3 months ago

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Jan 12, 2026, 9:00 AM EST - 3 months ago

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Jan 9, 2026, 9:00 AM EST - 3 months ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Jan 8, 2026, 9:00 AM EST - 3 months ago

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Jan 7, 2026, 9:00 AM EST - 3 months ago

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

Dec 16, 2025, 9:00 AM EST - 4 months ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Dec 9, 2025, 6:00 PM EST - 4 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Nov 20, 2025, 4:05 PM EST - 5 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Nov 19, 2025, 9:00 AM EST - 5 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oct 28, 2025, 7:30 AM EDT - 6 months ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 20, 2025, 9:00 AM EDT - 6 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Sep 29, 2025, 8:30 AM EDT - 7 months ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 16, 2025, 7:00 AM EDT - 7 months ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 8, 2025, 7:00 AM EDT - 7 months ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 2, 2025, 9:10 AM EDT - 8 months ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Aug 28, 2025, 8:30 AM EDT - 8 months ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 11, 2025, 4:55 PM EDT - 8 months ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 8, 2025, 9:05 AM EDT - 9 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:00 AM EDT - 9 months ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 5, 2025, 8:30 AM EDT - 9 months ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Jul 29, 2025, 8:30 AM EDT - 9 months ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 23, 2025, 9:39 AM EDT - 9 months ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 22, 2025, 3:32 PM EDT - 9 months ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 16, 2025, 8:30 AM EDT - 9 months ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 10, 2025, 8:30 AM EDT - 10 months ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 10 months ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 1 year ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 1 year ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 7, 2025, 9:24 PM EST - 1 year ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Jan 22, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 15, 2025, 7:02 AM EST - 1 year ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Dec 23, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

saxy4u Apr. 18 at 6:39 PM

$ONCY AIO GOBLET RECRUITMENT COMPLETED UPDATED 116/137 INCLUDED UPDATED APRIL 17 2026 https://www.aio-portal.de/studie/108--goblet.html

0 · Reply

saxy4u Apr. 18 at 5:04 PM

0 · Reply

EscapePlan Apr. 18 at 12:46 PM

5 · Reply

saxy4u Apr. 18 at 2:35 AM

$ONCY AstraZeneca, Pfizer and Roche!

3 · Reply

saxy4u Apr. 17 at 8:58 PM

$ONCY see everyone Monday! Let’s all hope we get what we want! Cheers

0 · Reply

GoPatzGo123 Apr. 17 at 7:34 PM

$ONCY fuck all here so far.

1 · Reply

uptrend2025 Apr. 17 at 5:45 PM

$ONCY 👀

0 · Reply

m00nsh0t Apr. 17 at 4:34 PM

$ONCY getting some action to the upside

0 · Reply

saxy4u Apr. 17 at 2:49 PM

$ONCY $1.25 EOD?

2 · Reply

GoPatzGo123 Apr. 17 at 11:18 AM

$ONCY this thanks @saxy4u 👇👇👇👇👇👇👇👇👇

1 · Reply

GoPatzGo123 Apr. 17 at 11:13 AM

$ONCY had something positive leaked we would've seen a nice up tick to this stock. Is there some abstracts being presented today?

0 · Reply

Sanderstein Apr. 16 at 8:58 PM

$ONCY Not today, not tomorrow, not next week. Its always just a little longer!!!

0 · Reply

exwallstcfo Apr. 16 at 6:08 PM

$ONCY Watch for block trades .... The smart money will telegraph their intentions

0 · Reply

charlietwodogs Apr. 16 at 5:26 PM

$ONCY if you Google fda type c meeting. You will see that it could be up to 30 days to hear from them.... today is a big nothing Burger.

0 · Reply

EscapePlan Apr. 16 at 4:45 PM

$ONCY I'm assuming that we wont hear anything today re the meeting with FDA? Just need to be patient and wait....

1 · Reply

GoPatzGo123 Apr. 16 at 4:12 PM

$ONCY sorry about this post ...plz disregard

0 · Reply

GoPatzGo123 Apr. 16 at 2:39 PM

$ONCY lol bet you all got excited ??? I was just practicing for this afternoon

1 · Reply

saxy4u Apr. 16 at 1:44 PM

$ONCY Bid $1.08 Ask $1.40 today!!! Love to see 2 mill shorts cover after a Halt this afternoon! lol Wishful thinking of course. News Imminent!

1 · Reply

exwallstcfo Apr. 16 at 12:32 PM

I knew March was going to be a brutal month ... took heavy losses ....however March was going to be a very opportunistic month .... accumulated on all of my top 5 holdings .... those losses are all gone !!!! I see the best bull market in my lifetime imminent !! 1 $SOUN accumulated with 2028 calls plus shares 2 $BBAI accumulated with 2028 calls plus shares 3 $ONCY on payday watch 4 $ITMSF on payday watch 5 $HIMX a sleeper AI off the radar loaded up on 2nd tier holdings. FUBO AAL ONDS

1 · Reply

saxy4u Apr. 16 at 3:23 AM

$ONCY Abstracts released April 17 at 3pm EST

1 · Reply

saxy4u Apr. 15 at 10:48 PM

$ONCY remember that the AACR is this weekend so I don’t know if the data PR will be pre or post the weekend. On top of that, when we hear about the alignment with the FDA and if that sparks a partner or buyout! Could be an amazing 2 weeks! Don’t put sell stops cause the shorts will try to raid after the news is released. They have always short based on buy on the rumour short on the news old school shorting.

0 · Reply

XSeducr1X Apr. 15 at 8:21 PM

$ONCY let’s go! This has been one of those stocks just buying and holding! I feel like it’s gonna blow soon!

0 · Reply

Market Cap	123.10M
Revenue (ttm)	0.00
Net Income (ttm)	-28.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,050,800
Avg Vol	1,194,470
Day's Range	N/A - N/A
Shares Out	116.13M
Stochastic %K	100%
Beta	0.98
Analysts	Strong Sell
Price Target	$4.87